Earnings Call
Jul 15, 2026
Q2 FY2026
EPS Estimate
6.21
EPS Actual
7.45
Post-Earnings Close
$390.33
Earnings Reaction
-8.5%
Elevance Health's second quarter print came in ahead of internal expectations, with adjusted diluted EPS of $7.45 driving a guidance raise to at least $27 for full-year 2026, a meaningful step up that management paired with a reaffirmed commitment to at least 12% adjusted EPS growth in 2027 off an elevated $26 baseline. The outperformance was broad-based rather than concentrated: roughly half came from Medicare Advantage, where deliberate 2026 portfolio repositioning, tighter plan design, a D-SNP and HMO-weighted product mix, and improved claims experience, is translating into tangible margin recovery toward the at-least-2% full-year target. The other half came from individual ACA, where a higher bronze-plan mix created more pronounced first-half seasonality and final 2025 CMS risk adjustment results came in favorable to prior estimates. Management was explicit that it is not extrapolating either source of favorability into the back half, reestablishing the majority of the risk adjustment benefit in current-year accruals and flagging that ACA market dynamics remain fluid.
Report generated on Jul 15, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full ELV analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.